1. Introduction {#sec1}
===============

Antiphospholipid antibodies (APA) are a heterogeneous group of antibodies that are detected in a variety of conditions, including primary antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) \[[@B1]\]. The term antiphospholipid antibodies is a misnomer as APA present in autoimmune disease, like SLE, do not bind to phospholipids but recognize phospholipid-binding proteins \[[@B2]\]. Patients with persistent APA who develop pregnancy complications or thrombosis are considered to have primary APS and those who develop these complications in the presence of autoimmune disease are classified having secondary APS. Since the definition of APS is not limited to a single APA assay, it is required to measure more than one APA. Indeed, currently recognized laboratory criteria for APS include having one or more of three APA, including anticardiolipin antibodies (ACL), lupus anticoagulant (LAC), or anti-*β* ~2~ glycoprotein I antibodies (anti-*β* ~2~GPI) in conjunction with the presence of thrombosis or pregnancy loss \[[@B3]\].

Although the genetic basis of APA \[[@B4]\] and APS \[[@B5]\] has been suggested, the underlying genetic factors have not been clearly established. Understanding the genetic bases of various APA may help to delineate the mechanisms for APS. The objective of this study was to perform a genome-wide association study (GWAS) in an effort to identify loci/genes for the three main APA, namely, ACL, LAC, and anti-*β* ~2~GPI.

2. Subjects and Methods {#sec2}
=======================

2.1. Subjects {#sec2.1}
-------------

A subset of individuals from our larger GWAS of SLE (unpublished data) that had the ACL (*n* = 670), LAC (*n* = 708), and anti-*β* ~2~GPI (*n* = 496) measurements available were used in this study. All individuals were women of European ancestry. The study participants included both SLE cases and controls and their characteristics are given in [Table 1](#tab1){ref-type="table"}. Our controls were apparently healthy individuals that were recruited from blood bank. We measured APA in our controls but they were not characterized for primary APS due to our study design that is focused on identifying genes for SLE and APA. Furthermore, there were only 28 individuals with APS, and this small number was not considered to be appropriate for a GWAS analysis. All subjects provided written informed consent and the study was approved by the Institutional Review Board.

2.2. Antiphospholipid Antibodies {#sec2.2}
--------------------------------

The presence of ACL (IgG \> 15 GPL units, IgM \> 10 MPL units, IncStar, Stillwater, MN, USA), LAC (partial thromboplastin time or Russell\'s viper venon time with mix) and anti-*β* ~2~GPI (QUANTA Lite *β* ~2~GPI screen, INOVA Diagnostics, Inc. San Diego, CA, USA) was tested in sera or plasma obtained from the study subjects. The three APA (ACL, LAC, and anti-*β* ~2~GPI) were classified into antibody-positive and antibody-negative groups based on manufacturer\'s protocols.

2.3. Genotyping and Quality Control (QC) {#sec2.3}
----------------------------------------

DNA samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 containing 906,600 SNPs at Expression Analysis, Durham, NC, USA. All samples used in this study passed strict quality control measurements in our larger GWAS. Exclusion criteria included samples with poor performance (\<95% average call rate across the array), poorly performing markers (44,592 with \<95% call rate across all samples genotyped), and markers with significant deviation from Hardy-Weinberg equilibrium (*P* ≤ 1*E* − 06) and with low minor allele frequency (MAF \<0.01). Population stratification analysis was conducted using a multidimensional scaling method implemented in PLINK. SNPs falling within the genomic regions with abnormal linkage disequilibrium patterns and structural variations (hg18; chr2: 130--140 Mb, chr6: 24--36 Mb, chr8: 8--12 Mb, chr11: 42--58 Mb, and chr17: 40--43 Mb) were excluded from the principal component (PC) analysis but were included in subsequent association analysis. First 4 components were determined to be relevant for the determination of population origin based on visual examination of PC plots and were used as covariates in the association statistics.

2.4. Association Analysis {#sec2.4}
-------------------------

The three APA (ACL, LAC, and anti-*β* ~2~GPI) were classified into antibody-positive and antibody-negative groups based on manufacturer\'s protocols. Association of SNPs with the antibody status was tested using logistic regression under the additive model. Considering the effect of SNPs on the antibody status may be confounded by the disease status (SLE) and other demographic variables (age, BMI, smoking), we used the stepwise regression method to select the most parsimonious set of covariates for each dependent variable. The analysis for each antibody was adjusted for the disease status (SLE) and the first four principal components. In addition, the ACL and LAC analyses were adjusted for smoking and BMI, respectively. *R* and/or PLINK statistical software programs were used for all analyses performed for this study.

3. Results {#sec3}
==========

3.1. Quantile-Quantile Plots of the GWAS Data {#sec3.1}
---------------------------------------------

The genome-wide association analysis was performed on 670 individuals with ACL, 708 individuals with LAC and 496 individuals with anti-*β* ~2~GPI ([Table 1](#tab1){ref-type="table"}) who were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. [Figure 1](#fig1){ref-type="fig"} shows the quantile-quantile plots for comparisons of observed and expected *P* values distribution for ACL, LAC, and anti-*β* ~2~GPI. For all three APA, the distribution of observed *P* values conformed to the null distribution until the tail of the distribution where it deviated, indicating no evidence of significant population stratification but evidence of genetic association.

3.2. Association with Anticardiolipin Antibodies (ACL) {#sec3.2}
------------------------------------------------------

[Figure 2](#fig2){ref-type="fig"} shows the genome-wide *P* values for ACL in a Manhattan plot and the top loci with *P* \< 1*E* − 04 are presented in [Table 2](#tab2){ref-type="table"}. Three top SNPs with *P* \< 1*E* − 05 were observed. The most significant SNP, rs6889746 (*P* = 6.02*E* − 06), was located upstream of *PELO* (Pelota homolog) on chromosome 5q11.2. The next top SNP, rs6681460 (*P* = 6.98*E* − 06), was present in *SGIP1* (SH3-domain GRB2-like-intercation protein1) on chromosome 1p31.3. There was a total of 28 SNPs in this region with *P* \< 1*E* − 03. The next top SNP, rs12204683 (*P* = 7.02*E* − 06), resided downstream of *LCA5* on chromosome 6q14.1.

3.3. Association with Lupus Anticoagulant (LAC) {#sec3.3}
-----------------------------------------------

The Manhattan plot for LAC is shown in [Figure 3](#fig3){ref-type="fig"} and the top hits with *P* \< 1*E* − 04 are given in [Table 3](#tab3){ref-type="table"}. The most significant SNP, rs1978968, was observed in *MICAL3*on chromosome 22q11.21 (*P* = 2.21*E* − 06) and there were additional 7 significant SNPs in this region with *P* \< 1*E* − 03. The next significant SNP was observed on chromosome 2p12 in *FAM176A* (rs17011455, *P* = 4.70*E* − 06). However, no other SNP with *P* \< 1*E* − 03 was observed in this region. The third significant SNP, rs17791782, was observed in *DSTN* on chromosome 20p12.1 (*P* = 6.54*E* − 06).

3.4. Association with Anti-*β* ~2~ Glycoprotein I Antibodies (Anti-*β* ~2~GPI) {#sec3.4}
------------------------------------------------------------------------------

Five loci on four chromosomes were observed at *P* \< 1*E* − 05 for association with anti-*β* ~2~GPI ([Figure 4](#fig4){ref-type="fig"}, [Table 4](#tab4){ref-type="table"}). The top SNP (rs10492418) at *P* = 2.05*E* − 06 was observed on chromosome 13q33.3 in *MYO16*. This chromosome also harbors another locus for anti-*β* ~2~GPI at 13q14.11 (rs9315762, *P* = 6.68*E* − 06), near a region expressing long intergenic nonprotein coding RNAs. The second most significant SNP, rs11975235, was observed in *PDE1C* on chromosome 7p14.3 (*P* = 2.88*E* − 06). The third most significant SNP was observed upstream of *TANK* on chromosome 2q24.2 (rs2357982, *P* = 3.38*E* − 06) that also harbored 12 additional significant SNPs with *P* \< 1*E* − 03.

3.5. Association with Presence of Two or More Antibodies {#sec3.5}
--------------------------------------------------------

In addition to the single-antibody analyses described above, we also performed an association analysis between individuals who were positive for two or more antibodies (*n* = 100) versus individuals who were negative for all three antibodies (*n* = 227). [Table 5](#tab5){ref-type="table"} shows the results of top loci with *P* \< 1*E* − 04. Interestingly, five of these loci (*SESTD1*, *CACNB2*, *TANK*, *TMEM45B,* and *FMN1*) overlapped with those observed in the anti-*β* ~2~GPI analysis (see [Table 4](#tab4){ref-type="table"}) and two (*DSTN* and *BFSP1*) overlapped with those observed in the LAC analysis (see [Table 3](#tab3){ref-type="table"}). Although the most significant locus, *DYNLRB2* (*P* = 1.44*E* − 06), was not among the top loci detected in any of the single-antibody analyses, the second most significant locus, *SESTD1* (*P* = 6.08*E* − 06), also showed association with anti-*β* ~2~GPI.

3.6. Association of Extended Major Histocompatibility Complex (xMHC) Region and Apolipoprotein H (APOH) with APA {#sec3.6}
----------------------------------------------------------------------------------------------------------------

Previously, several studies have reported genetic association of the human leukocyte antigen (HLA) genes located at the MHC locus on chromosome 6p21 with the presence of APA \[[@B6]\]. Likewise, since *β* ~2~GPI is the main target antigen for APA, genetic variation in its gene, *APOH*, is expected to be associated with the occurrence of APA. Although no SNPs from either the HLA genes or *APOH* were among the top GWAS SNPs with *P* \< 1*E* − 04 (Tables [2](#tab2){ref-type="table"}--[5](#tab5){ref-type="table"}), the xMHC region revealed 104, 191, and 108 significant SNPs (*P* \< 0.05) to be associated with ACL, LAC, and anti-*β* ~2~GPI, respectively. [Table 6](#tab6){ref-type="table"} lists significant SNPs with *P* \< 0.01 in the MHC region for the three APA examined. Most significant SNPs were observed in or near *HLA-DPB1*, *HLA-DPB2*, *HLA-DPA1*, *HLA-DQA1*, *HLA-DQA2,* and *HLA-DMA*. Noteworthy, some SNPs were associated with more than one APA. For example, among the SNPs located upstream of *HLA-DQA2*, rs9275765 and rs9275772 were associated with LAC (*P* = 7.86*E* − 04) and anti-*β* ~2~GPI (*P* = 3.15*E* − 03), rs9275793 with LAC (*P* = 8.84*E* − 04) and anti-*β* ~2~GPI (*P* = 3.10*E* − 03), and rs9276298 with LAC (*P* = 1.33*E* − 03) and anti-*β* ~2~GPI (*P* = 5.23*E* − 03). Likewise, rs2395357 near *HLA-DPB2* showed association with ACL (*P* = 4.34*E* − 04) and LAC (*P* = 1.09*E* − 02) and rs11539216 in *HLA-DMA* with ACL (*P* = 9.96*E* − 04) and LAC (*P* = 9.29*E* − 03). Of the 21 QC-passed SNPs present in or near *APOH*, six revealed nominal associations with anti-*β* ~2~GPI, and the Trp316Ser variant (rs1801690) was the most significant SNP (*P* = 3.12*E* − 03) ([Table 7](#tab7){ref-type="table"}). Two additional SNPs also showed nominal associations with LAC (*P* = 0.026, 0.027).

4. Discussion {#sec4}
=============

The persistent presence of APA, such as ACL, LAC, or anti-*β* ~2~GPI, may lead to the development of antiphospholipid syndrome (APS), which may occur alone (primary APS) or in the presence of an autoimmune disease (secondary APS). Although the genetic basis of APA and APS has been suggested \[[@B4], [@B5]\], the precise identity of the causative genes is largely unknown. Here we report the first GWAS focused on identifying the susceptibility loci/genes for the occurrence of three main APA, namely, ACL, LAC, and anti-*β* ~2~GPI.

Initially, we performed separate genome-wide analyses for the three APA because the antigen specificity of APA is highly heterogeneous and each APA may have different genetic determinants. This seems to be confirmed in our GWAS results where none of the top loci for the three APA overlapped (see Tables [2](#tab2){ref-type="table"}--[4](#tab4){ref-type="table"}). However, a single-antibody analysis may include individuals who are positive for more than one antibody in the antibody-positive group or may include individuals in the antibody-negative group who are positive for another antibody, which might have an effect on the genetic association outcome. In order to address this potential problem, we performed an additional genome-wide analysis on individuals who were positive for two or more APA as they presumably would have a higher genetic load of APA susceptibility genes and compared them with those who were negative for all three APA tested. Noteworthy, seven of the top loci observed in the latter analysis overlapped with the top loci observed in the individual analyses of anti-*β* ~2~GPI and LAC (see [Table 5](#tab5){ref-type="table"}). Although none of the observed top loci in any analysis met the strict criteria for genome-wide level of significance (*P* \< 5*E* − 08), we have identified a number of suggestive genomic regions with *P* \< *E* − 05 that are worthy of follow-up studies in independent samples. They include loci harboring *DYNLRB2* (*P* = 1.44*E* − 06) and *SESTD1* (*P* = 6.08*E* − 06) for individuals positive for at least two APA;*PELO*(*P* = 6.02*E* − 06), *SGIP1* (*P* = 6.98*E* − 06), and *LCA5* (*P* = 7.02*E* − 06) for ACL; *MICAL3*(*P* = 2.21*E* − 06), *FAM176A* (*P* = 4.70*E* − 06), and *DSTN*(*P* = 6.54*E* − 06) for LAC; and *MYO16*(*P* = 2.05*E* − 06), *PDE1C*(*P* = 2.88*E* − 06), *TANK*(*P* = 3.38*E* − 06), *FLJ42392* (*P* = 6.68*E* − 06), and *MACROD2*(*P* = 6.86*E* − 06) for anti-*β* ~2~GPI.

While many of these loci are of unknown function in antibody production, some of them harbor candidate genes known to be involved in immune response and thus may be relevant to the production of APA. For example,*DYNLRB2*is involved in immune signaling and genetic variation in this gene is associated with tuberculosis susceptibility \[[@B7]\]. SESTD1 binds several phospholipid species \[[@B8]\] and may thus serve as an autoantigen for APA. TANK (TRAF family member-associated NFKB activator) is believed to be important in type 1 interferon production \[[@B9]\] and has been suggested to play a role in hepatitis B and C infections \[[@B10], [@B11]\]. The *MYO16* (myosin XVI) locus has recently been implicated in diabetic nephropathy \[[@B12]--[@B14]\]. Interestingly, the presence of APA or APS is a strong risk factor for nephropathy \[[@B15]--[@B17]\] and one study has suggested that anti-*β* ~2~GPI may be protective against lupus nephritis and renal damage \[[@B18]\]. FAM176A (a.k.a *TMEM166*) has been implicated in autophagy and apoptosis \[[@B19]\], two mechanisms with suggested roles in autoimmunity \[[@B20], [@B21]\].

Before the GWAS era, the focus of genetic studies on APA was mainly on candidate genes, with a major emphasis on HLA genes located at the MHC locus and to some extent on *APOH*. Since none of our top hits included SNPs from either the HLA genes or *APOH*, we examined the extent of association signals in these genomic regions. Indeed, we found a number of promising significant SNPs near or in various HLA genes to be associated with ACL, LAC, and anti-*β* ~2~GPI (see [Table 6](#tab6){ref-type="table"}). Our findings are consistent with previous reports that also found multiple associations of HLA genes with these autoantibodies \[[@B6]\]. Previous findings regarding the association of *APOH* coding SNPs with APA have been inconsistent because of the conflicting reports \[[@B6], [@B22]\]. In our sample, we found six *APOH* SNPs to be associated with anti-*β* ~2~GPI and the most significant SNP was rs1801690 (Trp316Ser) (see [Table 7](#tab7){ref-type="table"}) that is located in the 5th domain of *β* ~2~GPI affecting the phospholipid-binding site \[[@B23]\]. Another coding SNP in *APOH*, rs3176975 (Val247Leu), that has been reported to be associated with APS \[[@B22]\], showed only a modest trend for association in our sample (odds ratio 1.21; *P* = 0.286). The replication of previously reported HLA and *APOH* findings with similar association signals serve as positive controls for our GWAS. On the other hand, it also indicates that HLA and *APOH* are not among the top loci for APA and thus our focus should be on the identification and characterization of other genes that are more relevant to the production of APA.

In conclusion, to the best of our knowledge, this is the first GWAS that has attempted to delineate the genetic basis of three main APA, namely, ACL, LAC, and anti-*β* ~2~GPI. Although we did not identify loci meeting the conservative threshold of genome-wide significance, we have identified a number of suggestive novel loci for APA that will stimulate follow-up studies in independent and larger sample sets to replicate our findings. The main limitations of our study include relatively small sample size and lack of a replication sample; however, our top SNPs provide a select group of suggestive candidate loci/genes that can easily be tested for replication by other research groups, which would also enable a subsequent meta-analysis with increased power.
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###### 

Characteristics of study participants with three antiphospholipid antibodies in the GWAS dataset\*.

                  ACL             LAC             Anti-*β* ~2~GPI                                   
  --------------- --------------- --------------- ----------------- --------------- --------------- ---------------
  Mean age ± SD   46.92 ± 11.41   46.19 ± 10.85   45.64 ± 11.35     46.40 ± 11.36   45.91 ± 10.68   46.79 ± 11.18
  SLE cases (%)   58.5            58.1            70.8              56.3            71.3            51.9
  Controls (%)    41.5            41.9            29.2              43.7            28.7            48.1

\*ACL: anticardiolipin antibodies; LAC: lupus anticoagulant; Anti-*β* ~2~GPI: anti-*β* ~2~ glycoprotein I antibodies.

###### 

Genetic loci associated with the occurrence of ACL with *P* \< 1*E* − 04\*.

  CHR   Gene             Lead SNP     BP             Total SNPs   MAF       OR        *P*      
  ----- ---------------- ------------ -------------- ------------ --------- --------- -------- --------------
  5     *PELO*           rs6889746    51742663       3            0.3534    0.5       1.776    6.02*E* − 06
  1     *SGIP1*          rs6681460    66895645       28           0.3755    0.5168    1.827    6.98*E* − 06
  6     *LCA5*           rs12204683   80212978       4            0.2378    0.3701    1.877    7.02*E* − 06
  4     *MIR4275*        rs17642174   28160435       6            0.1355    0.2346    2.021    1.42*E* − 05
  4     *C4orf37*        rs13134014   99323902       21           0.1517    0.2542    1.928    1.76*E* − 05
  7     *BZW2*           rs6961256    16697717       3            0.01261   0.05587   5.214    1.96*E* − 05
  2     *FAM49A*         rs6753768    16483918       11           0.2836    0.1648    0.5016   2.37*E* − 05
  4     *MAD2L1*         rs10518344   1.21*E* + 08   3            0.05136   0.1178    2.696    2.77*E* − 05
  11    *KIRREL3*        rs1793667    1.26*E* + 08   1            0.2789    0.3966    1.781    2.89*E* − 05
  14    *YLPM1*          rs2241275    74321193       7            0.435     0.5587    1.754    3.06*E* − 05
  14    *PROX2*          rs4899536    74386367       2            0.4331    0.5559    1.752    3.28*E* − 05
  2     *ATL2*           rs6749177    38531205       11           0.4958    0.3659    0.576    3.77*E* − 05
  17    *PRPSAP1*        rs11077813   71848140       1            0.2704    0.1564    0.5072   3.82*E* − 05
  9     *TTLL11*         rs10985483   1.24*E* + 08   4            0.3703    0.25      0.5571   4.09*E* − 05
  8     *ZBTB10*         rs406629     81620942       6            0.3795    0.2599    0.5501   4.26*E* − 05
  21    *LINC00317*      rs2827107    22175926       3            0.2128    0.3156    1.847    5.63*E* − 05
  7     *NUPL2*          rs10232205   23197079       1            0.09244   0.02793   0.2465   6.22*E* − 05
  1     *DUSP10*         rs11118750   2.2*E* + 08    4            0.2174    0.3287    1.753    6.88*E* − 05
  15    *MCTP2*          rs1863095    92917093       1            0.3224    0.4511    1.665    6.90*E* − 05
  17    *SHPK*           rs222790     3478239        1            0.2051    0.3097    1.793    7.30*E* − 05
  6     *KHDRBS2*        rs2752976    63486388       11           0.431     0.5447    1.688    7.88*E* − 05
  5     *GLRA1*          rs154111     1.51*E* + 08   14           0.4569    0.3399    0.5875   7.91*E* − 05
  9     *MIR548AA1*      rs4836873    1.24*E* + 08   4            0.3651    0.2514    0.5746   8.29*E* − 05
  1     *LOC100505918*   rs16860501   1.67*E* + 08   1            0.09119   0.1648    2.116    8.89*E* − 05
  19    *OR7A10*         rs4808564    14825095       1            0.05126   0.1117    2.449    8.91*E* − 05
  9     *C9orf46*        rs4742085    5340548        2            0.3501    0.4678    1.696    9.02*E* − 05
  9     *PTPRD*          rs2484741    10477877       7            0.2977    0.1983    0.5439   9.79*E* − 05
  16    *PDXDC1*         rs3198697    15037441       1            0.3658    0.4859    1.646    9.83*E* − 05

\*CHR: chromosome; Gene: a plausible biological candidate gene in the locus or the nearest annotated gene to the lead SNP; Lead SNP: most significant SNP in the gene region; BP: base-pair position of the lead SNP; Total SNPs: total number of SNPs with *P* \< 1*E* − 03 in the gene region; MAF: minor allele frequencies in antibody-negative and antibody-positive groups; OR: odds ratio; *P*: *P*-values for the test.

###### 

Genetic loci associated with the occurrence of lupus anticoagulant (LAC) with *P* \< 1*E* − 04\*.

  CHR   Gene             Lead SNP     BP             Total SNPs   MAF        OR        *P*      
  ----- ---------------- ------------ -------------- ------------ ---------- --------- -------- --------------
  22    *MICAL3*         rs1978968    16828113       8            0.2144     0.3553    2.235    2.21*E* − 06
  2     *FAM176A*        rs17011455   75643997       1            0.01661    0.06967   5.211    4.70*E* − 06
  20    *DSTN*           rs17791782   17514069       2            0.07867    0.1721    2.628    6.54*E* − 06
  6     *SUPT3H*         rs9472374    44904278       1            0.01957    0.07083   4.77     1.14*E* − 05
  3     *LRIG1*          rs4549225    66850149       10           0.3735     0.5246    1.867    1.54*E* − 05
  1     *SMYD3*          rs7527610    2.45*E* + 08   2            0.005236   0.04098   10.19    1.77*E* − 05
  14    *PELI2*          rs754314     55822350       8            0.04833    0.1167    3.111    2.13*E* − 05
  20    *BFSP1*          rs16999416   17489830       1            0.08494    0.1777    2.412    2.32*E* − 05
  16    *NDRG4*          rs11862356   57067820       1            0.05846    0.1393    2.745    2.40*E* − 05
  17    *CDRT15P1*       rs7208809    13678048       2            0.06806    0.1516    2.573    2.62*E* − 05
  22    *FAM19A5*        rs9615320    47219591       2            0.1065     0.2008    2.333    3.07*E* − 05
  6     *SNRNP48*        rs17398435   7549105        1            0.06392    0.1446    2.589    3.45*E* − 05
  14    *OTX2*           rs12897597   56314078       1            0.1531     0.2667    2.097    3.53*E* − 05
  17    *RBFOX3*         rs16972153   74719776       1            0.04974    0.1148    2.925    3.59*E* − 05
  16    *MAF*            rs9935211    78440577       5            0.05467    0.1311    2.692    4.18*E* − 05
  5     *YTHDC2*         rs6865651    1.13*E* + 08   2            0.1848     0.3058    2.005    4.32*E* − 05
  10    *LDB3*           rs4934256    88490345       2            0.05507    0.123     2.783    4.68*E* − 05
  9     *KLF4*           rs1888617    1.1*E* + 08    1            0.2657     0.4009    1.935    4.92*E* − 05
  10    *TACC2*          rs12773310   1.24*E* + 08   6            0.3536     0.219     0.4945   5.19*E* − 05
  6     *LY86*           rs9328374    6536628        1            0.1875     0.307     1.989    5.40*E* − 05
  9     *ZCCHC7*         rs7031314    37366122       3            0.2204     0.3375    1.924    5.90*E* − 05
  3     *SETD5*          rs17050346   9456593        5            0.01926    0.06967   4.047    6.34*E* − 05
  4     *COL25A1*        rs13104799   1.1*E* + 08    6            0.2245     0.1107    0.4106   6.68*E* − 05
  7     *C7orf58*        rs12537243   1.2*E* + 08    1            0.09178    0.1736    2.289    7.22*E* − 05
  4     *RBM46*          rs7687314    1.56*E* + 08   6            0.4474     0.5902    1.808    7.25*E* − 05
  9     *LOC100506710*   rs10973184   37056617       1            0.09895    0.1885    2.252    7.33*E* − 05
  3     *EPHA6*          rs4318565    97564200       1            0.03369    0.08607   3.32     7.77*E* − 05
  11    *LOC283143*      rs1393275    1.15*E* + 08   3            0.05026    0.1261    2.595    7.90*E* − 05
  18    *MAPRE2*         rs573269     30863716       1            0.3129     0.4385    1.816    8.05*E* − 05
  13    *FARP1*          rs285031     97584032       1            0.1489     0.2438    2.092    8.11*E* − 05
  10    *ANXA2P3*        rs10822492   66751936       15           0.3439     0.219     0.5075   8.32*E* − 05
  6     *TBCC*           rs11759402   42831787       4            0.1658     0.2686    1.945    8.32*E* − 05
  4     *LNX1*           rs6831173    54085908       4            0.1337     0.2377    1.962    8.80*E* − 05
  4     *SLC7A11*        rs10440463   1.39*E* + 08   3            0.2073     0.3238    1.88     8.85*E* − 05
  1     *HHAT*           rs1028383    2.09*E* + 08   1            0.2248     0.3475    1.882    9.29*E* − 05
  11    *WT1*            rs2207549    32325033       2            0.4202     0.2833    0.5274   9.37*E* − 05
  4     *FAM198B*        rs17036867   1.59*E* + 08   12           0.02747    0.08621   3.54     9.54*E* − 05

\*CHR: chromosome; Gene: a plausible biological candidate gene in the locus or the nearest annotated gene to the lead SNP; Lead SNP: most significant SNP in the gene region; BP: base-pair position of the lead SNP; Total SNPs: total number of SNPs with *P* \< 1*E* − 03 in the gene region; MAF: minor allele frequencies in antibody-negative and antibody-positive groups; OR: odds ratio; *P*: *P*-values for the test.

###### 

Genetic loci associated with the occurrence of anti-*β* ~2~GPI antibodies with *P* \< 1*E* − 04\*.

  CHR   Gene          Lead SNP     BP          Total SNPs   MAF       OR        *P*      
  ----- ------------- ------------ ----------- ------------ --------- --------- -------- --------------
  13    *MYO16*       rs10492418   108178727   5            0.4292    0.6016    2.172    2.05*E* − 06
  7     *PDE1C*       rs11975235   32156065    4            0.4843    0.311     0.4675   2.88*E* − 06
  2     *TANK*        rs2357982    161594349   13           0.2359    0.3885    2.189    3.38*E* − 06
  13    *FLJ42392*    rs9315762    39639907    2            0.1535    0.2901    2.255    6.68*E* − 06
  20    *MACROD2*     rs6080100    15951406    7            0.2655    0.4275    2.086    6.86*E* − 06
  17    *CAMKK1*      rs758642     3733656     1            0.3314    0.4837    2.038    1.23*E* − 05
  14    *ITPK1*       rs8021497    92637371    6            0.2059    0.3508    2.101    1.26*E* − 05
  2     *SESTD1*      rs10186547   179921914   2            0.3853    0.5391    2.009    1.56*E* − 05
  10    *CACNB2*      rs12356676   18687510    6            0.2587    0.3943    2.134    1.80*E* − 05
  18    *LRRC30*      rs9965173    7201755     4            0.07887   0.1718    2.647    2.59*E* − 05
  3     *PEX5L*       rs9856007    181225431   3            0.2514    0.3817    1.976    3.68*E* − 05
  11    *TMEM45B*     rs10894119   129081436   1            0.1835    0.293     2.168    4.05*E* − 05
  10    *SFTA1P*      rs1000039    10597879    1            0.02254   0.08779   4.19     4.13*E* − 05
  9     *OR1J1*       rs2778636    124270913   2            0.2641    0.3931    1.955    4.43*E* − 05
  5     *RAPGEF6*     rs17671387   130911895   1            0.04507   0.1183    3.186    4.71*E* − 05
  2     *GMCL1*       rs4241261    69917164    3            0.4761    0.3308    0.5278   4.93*E* − 05
  14    *C14orf101*   rs7153196    56256660    2            0.362     0.229     0.4996   5.58*E* − 05
  9     *WNK2*        rs10821084   94991443    1            0.07627   0.1718    2.425    6.33*E* − 05
  10    *SLC16A9*     rs7082987    61007793    1            0.3663    0.2317    0.4886   6.46*E* − 05
  4     *GDEP*        rs11730315   81020089    2            0.1648    0.2829    2.075    7.24*E* − 05
  4     *ARHGAP24*    rs17010960   86938938    2            0.02254   0.07634   4.326    7.85*E* − 05
  13    *HTR2A*       rs582385     46343995    4            0.1624    0.2824    2.02     8.09*E* − 05
  15    *FMN1*        rs2444955    31199305    2            0.2211    0.355     1.974    8.10*E* − 05
  5     *CARTPT*      rs16869487   70976850    1            0.02841   0.09542   3.602    8.59*E* − 05
  2     *NEU2*        rs11695991   233608333   1            0.0169    0.0687    4.802    8.63*E* − 05
  17    *CA10*        rs203076     47354484    7            0.2944    0.1603    0.4729   8.70*E* − 05
  9     *C9orf135*    rs1389124    71669176    3            0.09943   0.1985    2.286    9.23*E* − 05
  20    *SMOX*        rs1764996    4070805     2            0.02817   0.07634   4.014    9.93*E* − 05

\*CHR: chromosome; Gene: a plausible biological candidate gene in the locus or the nearest annotated gene to the lead SNP; Lead SNP: most significant SNP in the gene region; BP: base-pair position of the lead SNP; Total SNPs: total number of SNPs with *P* \< 1*E* − 03 in the gene region; MAF: minor allele frequencies in antibody-negative and antibody-positive groups; OR: odds ratio; *P*: *P*-values for the test.

###### 

Genetic loci associated with the occurrence of two or more antiphospholipid antibodies (ACL, LAC, or Anti-*β* ~2~GPI) with *P* \< 1*E* − 04\*.

  CHR   Gene             Lead SNP     BP          Total SNPs   MAF       OR        *P*      
  ----- ---------------- ------------ ----------- ------------ --------- --------- -------- --------------
  16    *DYNLRB2*        rs8060581    78750106    6            0.02466   0.1406    6.714    1.44*E* − 06
  2     *SESTD1*         rs13403289   179924976   2            0.3857    0.5833    2.423    6.08*E* − 06
  1     *DNAH14*         rs3913653    223603694   11           0.543     0.3421    0.43     1.09*E* − 05
  10    *CACNB2*         rs10828616   18710023    6            0.2175    0.3698    2.538    1.11*E* − 05
  18    *EPB41L3*        rs7238186    5469093     2            0.213     0.3854    2.327    2.61*E* − 05
  1     *MAGI3*          rs11102625   113750976   5            0.4355    0.6146    2.298    2.75*E* − 05
  2     *TANK*           rs13010671   161593338   5            0.07442   0.1882    3.437    3.17*E* − 05
  7     *CNTNAP2*        rs12113442   145329124   1            0.1054    0.2188    2.938    3.43*E* − 05
  18    *ZNF519*         rs8093228    13989380    4            0.2152    0.3646    2.326    4.85*E* − 05
  3     *FAM198A*        rs7624799    43020807    3            0.1592    0.2969    2.466    5.00*E* − 05
  20    *DSTN*           rs17791782   17514069    2            0.07883   0.1927    3.086    5.06*E* − 05
  20    *BFSP1*          rs16999416   17489830    1            0.08371   0.2031    2.93     5.63*E* − 05
  13    *ANKRD20A9P*     rs7319595    18392986    1            0.3484    0.5213    2.337    5.75*E* − 05
  15    *TLE3*           rs10518889   68337482    4            0.2838    0.4427    2.231    6.17*E* − 05
  22    *CLTCL1*         rs8135222    17672446    1            0.1749    0.3281    2.293    6.19*E* − 05
  11    *TMEM45B*        rs10894119   129081436   1            0.1789    0.3158    2.432    6.25*E* − 05
  1     *GADD45A*        rs787480     67868460    1            0.2207    0.08854   0.3088   6.57*E* − 05
  20    *SPTLC3*         rs6105044    13065747    2            0.352     0.1979    0.4138   7.08*E* − 05
  6     *HIVEP1*         rs6908010    12325985    2            0.4753    0.3073    0.4688   7.11*E* − 05
  7     *CUX1*           rs427534     101673424   3            0.4439    0.2656    0.4569   7.28*E* − 05
  10    *MSMB*           rs7094791    51229942    1            0.3857    0.2396    0.4081   7.35*E* − 05
  8     *TPD52*          rs10090469   81396522    1            0.1099    0.2292    2.668    7.43*E* − 05
  14    *LOC100506433*   rs698322     47597316    1            0.3914    0.2344    0.4277   7.58*E* − 05
  6     *MMS22L*         rs1206164    97703068    1            0.2511    0.4219    2.212    8.26*E* − 05
  12    *CDK17*          rs11108526   95379901    2            0.02691   0.08333   5.95     8.40*E* − 05
  11    *PDGFD*          rs4754095    103278377   3            0.2851    0.1436    0.3771   8.83*E* − 05
  15    *FMN1*           rs2444955    31199305    2            0.1951    0.3474    2.408    8.89*E* − 05
  10    *SORCS1*         rs4918273    108715485   11           0.3597    0.5319    2.064    8.92*E* − 05

\*CHR: chromosome; Gene: a plausible biological candidate gene in the locus or the nearest annotated gene to the lead SNP; Lead SNP: most significant SNP in the gene region; BP: base-pair position of the lead SNP; Total SNPs: total number of SNPs with *P* \< 1*E* − 03 in the gene region; MAF: minor allele frequencies in antibody-negative (negative for ALC, ACL and anti-*β* ~2~GPI) and antibody-positive (positive for at least two of ALC, ACL or anti-*β* ~2~GPI) groups; OR: odds ratio; *P*: *P*-values for the test.

###### 

Significant SNPs with *P* \< 0.01 in the MHC region on chromosome 6 for ACL, LAC, and Anti-*β* ~2~GP1\*.

  Gene                       SNP          *P*
  -------------------------- ------------ ---------
  ACL                                     
                                          
  *HLA-DPB1*                 rs3128918    0.00028
  *HLA-DPB2*                 rs2395357    0.00043
  *HLA-DMA*                  rs11539216   0.00099
  *HLA-DQB2*                 rs10484564   0.00536
  *GNL1*                     rs9295888    0.00758
  *GNL1*                     rs9295873    0.00794
  *HLA-DOA*                  rs4713603    0.0081
  *RPP21*                    rs1548515    0.00842
  *GNL1*                     rs9461607    0.00863
  *GNL1*                     rs17411480   0.00863
  *RPP21*                    rs9261821    0.00863
  *RPP21*                    rs9261850    0.00863
  *RPP21*                    rs9261854    0.00863
  *RPP21*                    rs9261855    0.00863
  *RPP21*                    rs1548513    0.00863
  *RPP21*                    rs9261925    0.00863
  *RPP21*                    rs9261926    0.00863
  *BRD2*                     rs17840186   0.00939
  *RPP21*                    rs9261799    0.00955
                                          
  LAC                                     
                                          
  *TAP2*                     rs1044043    0.00029
  *HLA-DQA1*                 rs642093     0.00032
  *AIF1*                     rs2736177    0.00041
  *HLA-DQA2*                 rs9275765    0.00078
  *HLA-DQA2*                 rs9275772    0.00078
  *HLA-DQA2*                 rs9275793    0.00088
  *HLA-DQA1*                 rs9272346    0.00130
  *HLA-DQA2*                 rs9276298    0.00133
  *HLA-DQA1*                 rs9272219    0.00167
  *C6orf10*                  rs3129934    0.00168
  *HLA-DQA1*                 rs9272535    0.00179
  *HLA-DRB1*                 rs674313     0.00215
  *HLA-DRB1*                 rs502771     0.00227
  *HLA-DRB1*                 rs9270986    0.00250
  *AIF1*                     rs2857597    0.00257
  *HCG26*                    rs2516516    0.00282
  *HLA-DRB1*                 rs615672     0.00295
  *HLA-DRB1*                 rs502055     0.00300
  *HLA-DQA1*                 rs9272723    0.00329
  *LOC100294145*             rs9276915    0.00352
  *C6orf10*                  rs2894254    0.00372
  *UBD*                      rs9368606    0.00403
  *C6orf10*                  rs3129900    0.00458
  *MCCD1*                    rs2734573    0.00553
  *PRRC2A*                   rs1046080    0.00618
  *C6orf10*                  rs7767325    0.00623
  *C6orf15*                  rs2517448    0.00627
  *C6orf10*                  rs3132928    0.00640
  *HLA-H*                    rs3132722    0.00675
  *HLA-DQB2*                 rs2857210    0.00685
  *HLA-DRA*                  rs3129868    0.00731
  *ATP6V1G2-DDX39B/DDX39B*   rs933208     0.00740
  *NFKBIL1*                  rs2857605    0.00755
  *TRIM26*                   rs3132671    0.00757
  *HLA-DQB1*                 rs3129716    0.00770
  *MSH5/MSH5-C6orf26*        rs3131379    0.00849
  *MSH5/MSH5-C6orf26*        rs3130484    0.00901
  *PSMB9*                    rs9276832    0.00907
  *BTNL2*                    rs2213581    0.00922
  *HLA-DMA*                  rs11539216   0.00929
  *ATP6V1G2-DDX39B/DDX39B*   rs3093978    0.00957
  *C6orf10*                  rs2143461    0.00986
  *TUBB*                     rs3095330    0.00990
  *LOC100294145*             rs4959119    0.00992
  *TRIM26*                   rs2517611    0.00993
                                          
  Anti-*β* ~2~GPI                         
                                          
  *HLA-DPB2*                 rs9277916    0.00147
  *HLA-DQA2*                 rs9275793    0.00310
  *HLA-DQA2*                 rs9275765    0.00315
  *HLA-DQA2*                 rs9275772    0.00315
  *HLA-DPA1*                 rs3130182    0.00331
  *HLA-DQB1*                 rs9469220    0.00372
  *HLA-DPB2*                 rs4711314    0.00378
  *HLA-DQA2*                 rs2647089    0.00463
  *HLA-DQA2*                 rs9276298    0.00523
  *HLA-DQB1*                 rs9275356    0.00526
  *HLA-DQA2*                 rs17615250   0.00710
  *HLA-DQA2*                 rs9275618    0.00807

\*ACL: anticardiolipin antibodies; LAC: lupus anticoagulant; Anti-*β* ~2~GPI: anti-*β* ~2~ glycoprotein I antibodies; Gene: a plausible biological candidate gene in the locus or the nearest annotated gene to the SNP; SNP: single-nucleotide polymorphism; *P*: *P*-values for the test.

###### 

Odds ratios and *P*-values for the association analysis of *APOH* SNPs on chromosome 17 with ACL, LAC, and anti-*β* ~2~GPI\*.

  SNP          BP         ACL      LAC      Anti-*β* ~2~GPI                      
  ------------ ---------- -------- -------- ----------------- --------- -------- ----------
  rs1801690    61638747   0.7655   0.4048   0.6444            0.2614    2.461    0.003122
  rs17769836   61663751   0.8968   0.4457   1.004             0.9821    0.5978   0.004849
  rs2873966    61642435   0.9519   0.7168   0.9858            0.9262    0.6224   0.005407
  rs7215391    61662484   0.8932   0.4391   0.984             0.9227    0.6146   0.008069
  rs8073418    61678134   0.9639   0.7759   0.8949            0.455     0.6661   0.01061
  rs8064837    61673165   0.9833   0.8915   1.011             0.9388    1.404    0.02235
  rs10491174   61685021   1.017    0.9335   0.765             0.2665    1.487    0.07256
  rs2215413    61679959   0.9418   0.6397   0.842             0.2435    0.829    0.221
  rs16958979   61654321   0.8586   0.5569   0.4332            0.02739   1.375    0.2253
  rs8178822    61655991   0.8748   0.6127   0.407             0.0258    1.379    0.2345
  rs12452959   61635526   0.8991   0.5748   1.196             0.3965    1.275    0.2541
  rs4791079    61640002   1.128    0.3573   1.206             0.2028    1.181    0.2802
  rs3176975    61641219   0.9723   0.8552   0.9923            0.9649    1.209    0.2858
  rs8066294    61673500   1.094    0.5597   1.014             0.9365    1.162    0.3981
  rs17763430   61635203   0.998    0.9904   0.8987            0.5811    0.8448   0.4051
  rs17690171   61633319   0.9893   0.9435   1.172             0.3479    1.141    0.4528
  rs16959003   61671199   1.105    0.6095   0.8378            0.4548    1.14     0.5639
  rs735866     61670208   1.206    0.3459   0.8419            0.4765    1.117    0.642
  rs7208089    61689374   1.091    0.5465   0.7956            0.1906    1.08     0.6476
  rs7222710    61630703   1.089    0.5011   1.016             0.9143    0.942    0.6896
  rs6933       61638692   1.126    0.3408   1.068             0.6431    1.02     0.8948

\**APOH*: apolipoprotein H; SNP: single-nucleotide polymorphism; BP: base-pair position; OR: odds ratio; *P*: *P*-values. ACL: anticardiolipin antibodies; LAC: lupus anticoagulant; Anti-*β* ~2~GPI: anti-*β* ~2~ glycoprotein I antibodies.
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